Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives.
CAR-T cells
HER2-positive breast cancer
antibody–drug conjugates
immune checkpoint inhibitors
immunotherapy
vaccines
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
25 Apr 2022
25 Apr 2022
Historique:
received:
29
03
2022
revised:
20
04
2022
accepted:
22
04
2022
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
15
5
2022
Statut:
epublish
Résumé
Breast cancer is the most common malignancy among women worldwide, and HER2-positive breast cancer accounts for approximately 15% of all breast cancer diagnoses. The advent of HER2-targeting therapies has dramatically improved the survival of these patients, significantly reducing their risk of recurrence and death. However, as a significant proportion of patients ultimately develop resistance to these therapies, it is extremely important to identify new treatments to further improve their clinical outcomes. Immunotherapy has revolutionized the treatment and history of several cancer types, and it has already been approved as a standard of care for patients with triple-negative breast cancer. Based on a strong preclinical rationale, immunotherapy in HER2-positive breast cancer represents an intriguing field that is currently under clinical investigation. There is a close interplay between HER2-targeting therapies (both approved and under investigation) and the immune system, and several new immunotherapeutic strategies, including immune checkpoint inhibitors, CAR-T cells and therapeutic vaccines, are being studied in this disease. In this narrative review, we discuss the clinical evidence and the future perspectives of immunotherapy for patients with HER2-positive breast cancer.
Identifiants
pubmed: 35565264
pii: cancers14092136
doi: 10.3390/cancers14092136
pmc: PMC9105460
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Italian Association for Cancer Research
ID : 5x1000, 2019 - ID. 22759, program, G.L. Alberto Zambelli
Organisme : Lombardy Region: Fondazione Regionale per la Ricerca Biomedica
ID : project FRBB-2015-0042
Organisme : Plagencell
ID : CP_10/2018
Références
Arch Pathol Lab Med. 2018 Nov;142(11):1364-1382
pubmed: 29846104
Int J Cancer. 2018 Nov 1;143(9):2126-2132
pubmed: 29693245
Prog Tumor Res. 2015;42:30-43
pubmed: 26377084
Ann Oncol. 2017 Apr 1;28(4):855-861
pubmed: 28119295
Lancet. 2021 May 8;397(10286):1750-1769
pubmed: 33812473
J Clin Oncol. 2021 May 1;39(13):1448-1457
pubmed: 33539215
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
Cancers (Basel). 2021 Jun 09;13(12):
pubmed: 34207890
J Clin Oncol. 2007 Aug 20;25(24):3680-7
pubmed: 17704416
Expert Opin Investig Drugs. 2022 Jun;31(6):567-591
pubmed: 35240902
Mol Cancer Ther. 2021 Aug;20(8):1442-1453
pubmed: 34045233
Lancet Oncol. 2020 Oct;21(10):1283-1295
pubmed: 33002436
N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
Cancer Discov. 2016 Dec;6(12):1382-1399
pubmed: 27663893
Ann Transl Med. 2019 Mar;7(5):105
pubmed: 31019955
Cancer Sci. 2016 Dec;107(12):1730-1735
pubmed: 27727484
Lancet Oncol. 2019 Mar;20(3):371-382
pubmed: 30765258
Oncologist. 2011;16(8):1092-100
pubmed: 21572124
Ann Oncol. 2018 Nov 1;29(11):2232-2239
pubmed: 30203045
J Natl Cancer Inst. 2019 Jun 1;111(6):538-549
pubmed: 30859213
J Clin Oncol. 2009 Dec 10;27(35):5911-8
pubmed: 19805669
Lancet Oncol. 2021 Aug;22(8):1139-1150
pubmed: 34339645
J Clin Oncol. 2019 Sep 1;37(25):2206-2216
pubmed: 31157583
Eur J Cancer. 2022 Jan;160:150-174
pubmed: 34823982
Mol Cancer Ther. 2015 Mar;14(3):692-703
pubmed: 25589493
Oncologist. 2022 Apr 5;27(4):e313-e327
pubmed: 35380716
Hum Gene Ther. 2012 Oct;23(10):1043-53
pubmed: 22780919
Lancet Oncol. 2020 Apr;21(4):519-530
pubmed: 32171426
Ann Oncol. 2021 Dec;32(12):1537-1551
pubmed: 34500046
Clin Cancer Res. 2016 Oct 15;22(20):5097-5108
pubmed: 27026201
Clin Cancer Res. 2019 Jul 15;25(14):4248-4254
pubmed: 31036542
Sci Transl Med. 2015 Nov 25;7(315):315ra188
pubmed: 26606967
N Engl J Med. 2022 Feb 10;386(6):556-567
pubmed: 35139274
Chin J Cancer Res. 2012 Jun;24(2):143-50
pubmed: 23357961
Cancer J. 2011 Sep-Oct;17(5):359-71
pubmed: 21952287
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690
pubmed: 27184417
Mol Ther. 2014 May;22(5):1029-38
pubmed: 24572294
Clin Cancer Res. 2020 Jun 1;26(11):2515-2523
pubmed: 32071118
JCI Insight. 2020 Jul 23;5(14):
pubmed: 32544101
Cancers (Basel). 2021 Mar 01;13(5):
pubmed: 33804398
J Transl Med. 2013 Mar 08;11:62
pubmed: 23497415
Lancet Oncol. 2019 Aug;20(8):1124-1135
pubmed: 31257177
Eur J Cancer. 2007 Feb;43(3):497-509
pubmed: 17223541
Expert Opin Investig Drugs. 2021 Jan;30(1):5-11
pubmed: 33191799
Drugs Context. 2018 Feb 12;7:212520
pubmed: 29456568
NPJ Breast Cancer. 2019 Oct 29;5:37
pubmed: 31700993
Ann Oncol. 2015 Dec;26(12):2429-36
pubmed: 26387142
Lancet Oncol. 2017 Jan;18(1):52-62
pubmed: 27964843
Annu Rev Immunol. 2013;31:51-72
pubmed: 23157435
Eur J Cancer. 2021 Jan;142:63-82
pubmed: 33221598
Breast Cancer Res Treat. 2020 Jun;181(2):391-401
pubmed: 32323103
Ann Oncol. 2019 Mar 1;30(3):397-404
pubmed: 30475950
J Natl Cancer Inst. 2016 Jan 27;108(7):
pubmed: 26819347
Lancet. 2017 Jun 17;389(10087):2415-2429
pubmed: 27939064
Cancer Res. 2008 Nov 15;68(22):9280-90
pubmed: 19010901
Breast. 2017 Oct;35:142-150
pubmed: 28735162
Breast Cancer Res Treat. 2018 Feb;167(3):671-686
pubmed: 29063313
Am J Cancer Res. 2020 Feb 01;10(2):688-703
pubmed: 32195036
J Clin Oncol. 2020 Jun 10;38(17):1887-1896
pubmed: 32058843
Breast. 2016 Oct;29:241-50
pubmed: 27481651
Lancet Oncol. 2016 Jun;17(6):791-800
pubmed: 27179402
Cancer Cell. 2010 Aug 9;18(2):160-70
pubmed: 20708157
Clin Cancer Res. 2018 Jan 1;24(1):95-105
pubmed: 29061641
Clin Cancer Res. 2009 Apr 15;15(8):2895-904
pubmed: 19351776
N Engl J Med. 2019 Feb 14;380(7):617-628
pubmed: 30516102
Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7142-7
pubmed: 21482773
Clin Cancer Res. 2021 Aug 15;27(16):4478-4485
pubmed: 33753456
JAMA Oncol. 2021 Apr 01;7(4):573-584
pubmed: 33480963
Expert Rev Clin Immunol. 2021 Mar;17(3):209-223
pubmed: 33481629
BMJ. 2021 Dec 21;375:e066381
pubmed: 34933868
Clin Cancer Res. 2016 May 1;22(9):2105-10
pubmed: 26867935
Curr Oncol Rep. 2021 Mar 24;23(5):57
pubmed: 33763756
J Biotechnol. 2012 Dec 31;162(2-3):171-82
pubmed: 22981627
Lancet Oncol. 2017 Jun;18(6):732-742
pubmed: 28526536
J Transl Med. 2010 Jun 07;8:53
pubmed: 20529245
J Clin Oncol. 2015 May 20;33(15):1688-96
pubmed: 25800760
Mol Ther. 2017 Sep 6;25(9):2214-2224
pubmed: 28602436
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Cancer Lett. 2020 Aug 1;484:1-8
pubmed: 32289441
Cancer Res. 2015 Sep 1;75(17):3596-607
pubmed: 26330166
Breast Cancer Res. 2018 Jun 22;20(1):62
pubmed: 29929548
Cancer Res. 2017 Oct 1;77(19):5374-5383
pubmed: 28819024
JAMA Oncol. 2019 Jan 1;5(1):74-82
pubmed: 30242306
Nat Rev Clin Oncol. 2016 Apr;13(4):228-41
pubmed: 26667975
Ann Oncol. 2019 Mar 1;30(3):405-411
pubmed: 30475947
Lancet Oncol. 2014 Feb;15(2):e58-68
pubmed: 24480556
Arch Immunol Ther Exp (Warsz). 2020 Jan 9;68(1):2
pubmed: 31915932
FASEB J. 2020 Aug;34(8):11185-11199
pubmed: 32645243